

Stanley H Appel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8496578/publications.pdf>

Version: 2024-02-01

92
papers

10,867
citations

53794

45
h-index

51608

86
g-index

114
all docs

114
docs citations

114
times ranked

10458
citing authors

#	ARTICLE	IF	CITATIONS
1	Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways. <i>Science</i> , 2015, 347, 1436-1441.	12.6	823
2	A unifying hypothesis for the cause of amyotrophic lateral sclerosis, parkinsonism, and alzheimer disease. <i>Annals of Neurology</i> , 1981, 10, 499-505.	5.3	755
3	Wild-type microglia extend survival in PU.1 knockout mice with familial amyotrophic lateral sclerosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 16021-16026.	7.1	647
4	Natural history of amyotrophic lateral sclerosis in a database population Validation of a scoring system and a model for survival prediction. <i>Brain</i> , 1995, 118, 707-719.	7.6	627
5	CD4+ T cells support glial neuroprotection, slow disease progression, and modify glial morphology in an animal model of inherited ALS. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 15558-15563.	7.1	401
6	Protein modification by the lipid peroxidation product 4-hydroxynonenal in the spinal cords of amyotrophic lateral sclerosis patients. <i>Annals of Neurology</i> , 1998, 44, 819-824.	5.3	355
7	Transformation from a neuroprotective to a neurotoxic microglial phenotype in a mouse model of ALS. <i>Experimental Neurology</i> , 2012, 237, 147-152.	4.1	346
8	The role of calcium-binding proteins in selective motoneuron vulnerability in amyotrophic lateral sclerosis. <i>Annals of Neurology</i> , 1994, 36, 846-858.	5.3	328
9	Endogenous regulatory T lymphocytes ameliorate amyotrophic lateral sclerosis in mice and correlate with disease progression in patients with amyotrophic lateral sclerosis. <i>Brain</i> , 2011, 134, 1293-1314.	7.6	323
10	Regulatory T lymphocytes mediate amyotrophic lateral sclerosis progression and survival. <i>EMBO Molecular Medicine</i> , 2013, 5, 64-79.	6.9	289
11	Ultrastructural evidence for altered calcium in motor nerve terminals in amyotrophic lateral sclerosis. <i>Annals of Neurology</i> , 1996, 39, 203-216.	5.3	274
12	Blood-spinal cord barrier breakdown and pericyte reductions in amyotrophic lateral sclerosis. <i>Acta Neuropathologica</i> , 2013, 125, 111-120.	7.7	263
13	Immune-mediated Mechanisms in the Pathoprosession of Amyotrophic Lateral Sclerosis. <i>Journal of NeuroImmune Pharmacology</i> , 2013, 8, 888-899.	4.1	253
14	Protective and Toxic Neuroinflammation in Amyotrophic Lateral Sclerosis. <i>Neurotherapeutics</i> , 2015, 12, 364-375.	4.4	236
15	Extracellular mutant SOD1 induces microglial-mediated motoneuron injury. <i>Glia</i> , 2010, 58, 231-243.	4.9	232
16	TREM2 Variant p.R47H as a Risk Factor for Sporadic Amyotrophic Lateral Sclerosis. <i>JAMA Neurology</i> , 2014, 71, 449.	9.0	221
17	Presence of 4-hydroxynonenal in cerebrospinal fluid of patients with sporadic amyotrophic lateral sclerosis. <i>Annals of Neurology</i> , 1998, 44, 696-699.	5.3	219
18	T cell-microglial dialogue in Parkinson's disease and amyotrophic lateral sclerosis: are we listening?. <i>Trends in Immunology</i> , 2010, 31, 7-17.	6.8	218

#	ARTICLE	IF	CITATIONS
19	Immune dysregulation in amyotrophic lateral sclerosis: mechanisms and emerging therapies. <i>Lancet Neurology</i> , The, 2019, 18, 211-220.	10.2	206
20	TDP-43 activates microglia through NF- κ B and NLRP3 inflammasome. <i>Experimental Neurology</i> , 2015, 273, 24-35.	4.1	174
21	TDP-43 Depletion in Microglia Promotes Amyloid Clearance but Also Induces Synapse Loss. <i>Neuron</i> , 2017, 95, 297-308.e6.	8.1	171
22	Neuroinflammation modulates distinct regional and temporal clinical responses in ALS mice. <i>Brain, Behavior, and Immunity</i> , 2011, 25, 1025-1035.	4.1	170
23	Activated Microglia Initiate Motor Neuron Injury by a Nitric Oxide and Glutamate-Mediated Mechanism. <i>Journal of Neuropathology and Experimental Neurology</i> , 2004, 63, 964-977.	1.7	147
24	Deciphering amyotrophic lateral sclerosis: What phenotype, neuropathology and genetics are telling us about pathogenesis. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2013, 14, 5-18.	1.7	142
25	Protective role of heme oxygenase-1 in oxidative stress-induced neuronal injury. , 1999, 56, 652-658.		141
26	ALS patients' regulatory T lymphocytes are dysfunctional, and correlate with disease progression rate and severity. <i>JCI Insight</i> , 2017, 2, e89530.	5.0	141
27	Mutant SOD1G93A microglia are more neurotoxic relative to wild-type microglia. <i>Journal of Neurochemistry</i> , 2007, 102, 2008-2019.	3.9	139
28	Role of Potassium Channels in Amyloid β -Induced Cell Death. <i>Journal of Neurochemistry</i> , 1998, 70, 1925-1934.	3.9	138
29	Protective effects of an anti-inflammatory cytokine, interleukin-4, on motoneuron toxicity induced by activated microglia. <i>Journal of Neurochemistry</i> , 2006, 99, 1176-1187.	3.9	138
30	Characterization of Gene Expression Phenotype in Amyotrophic Lateral Sclerosis Monocytes. <i>JAMA Neurology</i> , 2017, 74, 677.	9.0	130
31	Parvalbumin overexpression alters immune-mediated increases in intracellular calcium, and delays disease onset in a transgenic model of familial amyotrophic lateral sclerosis. <i>Journal of Neurochemistry</i> , 2001, 79, 499-509.	3.9	129
32	Expanded autologous regulatory T-lymphocyte infusions in ALS. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2018, 5, e465.	6.0	116
33	Regulatory T lymphocytes from ALS mice suppress microglia and effector T lymphocytes through different cytokine-mediated mechanisms. <i>Neurobiology of Disease</i> , 2012, 48, 418-428.	4.4	109
34	Serum C-Reactive Protein as a Prognostic Biomarker in Amyotrophic Lateral Sclerosis. <i>JAMA Neurology</i> , 2017, 74, 660.	9.0	96
35	Amyotrophic lateral sclerosis patient antibodies label Ca ²⁺ channel γ 1 subunit. <i>Annals of Neurology</i> , 1994, 35, 164-171.	5.3	91
36	Decremental motor responses to repetitive nerve stimulation in ALS. <i>Muscle and Nerve</i> , 1994, 17, 747-754.	2.2	85

#	ARTICLE	IF	CITATIONS
37	Antibodies to calcium channels from ALS patients passively transferred to mice selectively increase intracellular calcium and induce ultrastructural changes in motoneurons. <i>Synapse</i> , 1995, 20, 185-199.	1.2	81
38	Experimental autoimmune motoneuron disease. <i>Annals of Neurology</i> , 1989, 26, 368-376.	5.3	77
39	Defining SOD1 ALS natural history to guide therapeutic clinical trial design. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 99-105.	1.9	68
40	1 α , 25 dihydroxyvitamin D3-dependent up-regulation of calcium-binding proteins in motoneuron cells. , 1998, 51, 58.		64
41	Amyotrophic lateral sclerosis immunoglobulins increase Ca ²⁺ currents in a motoneuron cell line. <i>Annals of Neurology</i> , 1995, 37, 102-109.	5.3	62
42	Antibodies from patients with Parkinson's disease react with protein modified by dopamine oxidation. <i>Journal of Neuroscience Research</i> , 1998, 53, 551-558.	2.9	59
43	Phosphorylated TDP-43 (pTDP-43) aggregates in the axial skeletal muscle of patients with sporadic and familial amyotrophic lateral sclerosis. <i>Acta Neuropathologica Communications</i> , 2018, 6, 28.	5.2	59
44	Apoptotic Cell Death of a Hybrid Motoneuron Cell Line Induced by Immunoglobulins from Patients with Amyotrophic Lateral Sclerosis. <i>Journal of Neurochemistry</i> , 1994, 63, 2365-2368.	3.9	55
45	Clinical Significance of TDP-43 Neuropathology in Amyotrophic Lateral Sclerosis. <i>Journal of Neuropathology and Experimental Neurology</i> , 2017, 76, 402-413.	1.7	53
46	Red blood cell alterations in muscular dystrophy: The role of lipids. <i>Muscle and Nerve</i> , 1980, 3, 70-81.	2.2	50
47	Head-to-Head Comparison of ¹¹ C-PBR28 and ¹⁸ F-GE180 for Quantification of the Translocator Protein in the Human Brain. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1260-1266.	5.0	48
48	Restoring regulatory T-cell dysfunction in Alzheimer's disease through ex vivo expansion. <i>Brain Communications</i> , 2020, 2, fcaa112.	3.3	48
49	β -Amyloid-induced Neurotoxicity of a Hybrid Septal Cell Line Associated with Increased Tau Phosphorylation and Expression of β -Amyloid Precursor Protein. <i>Journal of Neurochemistry</i> , 1997, 69, 978-985.	3.9	47
50	Functional alterations of myeloid cells during the course of Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2018, 13, 61.	10.8	44
51	Peripheral nerve inflammation in ALS mice: cause or consequence. <i>Neurology</i> , 2012, 78, 833-835.	1.1	39
52	A robust, good manufacturing practice-compliant, clinical-scale procedure to generate regulatory T cells from patients with amyotrophic lateral sclerosis for adoptive cell therapy. <i>Cytotherapy</i> , 2016, 18, 1312-1324.	0.7	39
53	Inflammation in Parkinson's disease: Cause or consequence?. <i>Movement Disorders</i> , 2012, 27, 1075-1077.	3.9	38
54	Neonatal myasthenia gravis in the infant of a myasthenic mother in remission. <i>Annals of Neurology</i> , 1979, 6, 72-75.	5.3	37

#	ARTICLE	IF	CITATIONS
55	An open label study of a novel immunosuppression intervention for the treatment of amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2018, 19, 242-249.	1.7	35
56	Amyotrophic lateral sclerosis is a systemic disease: peripheral contributions to inflammation-mediated neurodegeneration. <i>Current Opinion in Neurology</i> , 2021, 34, 765-772.	3.6	35
57	MOLECULAR APPROACHES TO AMYOTROPHIC LATERAL SCLEROSIS. <i>Annual Review of Medicine</i> , 1995, 46, 133-145.	12.2	34
58	Elevated acute phase proteins reflect peripheral inflammation and disease severity in patients with amyotrophic lateral sclerosis. <i>Scientific Reports</i> , 2020, 10, 15295.	3.3	34
59	ALSFRS and appel ALS scores: Discordance with disease progression. <i>Muscle and Nerve</i> , 2008, 37, 668-672.	2.2	32
60	Pyrimethamine significantly lowers cerebrospinal fluid Cu/Zn superoxide dismutase in amyotrophic lateral sclerosis patients with <i>SOD1</i> mutations. <i>Annals of Neurology</i> , 2017, 81, 837-848.	5.3	32
61	Dipeptide repeat (DPR) pathology in the skeletal muscle of ALS patients with C9ORF72 repeat expansion. <i>Acta Neuropathologica</i> , 2019, 138, 667-670.	7.7	32
62	Ex vivo expansion of dysfunctional regulatory T lymphocytes restores suppressive function in Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2021, 7, 41.	5.3	32
63	Nigral damage and dopaminergic hypofunction in mesencephalon-immunized guinea pigs. <i>Annals of Neurology</i> , 1992, 32, 494-501.	5.3	31
64	Increased activation ability of monocytes from ALS patients. <i>Experimental Neurology</i> , 2020, 328, 113259.	4.1	30
65	Immunosuppressive Functions of M2 Macrophages Derived from iPSCs of Patients with ALS and Healthy Controls. <i>IScience</i> , 2020, 23, 101192.	4.1	27
66	Endogenous Inhibitor of Ligand Binding to the Muscarinic Acetylcholine Receptor. <i>Journal of Neurochemistry</i> , 1985, 44, 622-628.	3.9	24
67	The Role of Regulatory T Lymphocytes in Amyotrophic Lateral Sclerosis. <i>JAMA Neurology</i> , 2018, 75, 656.	9.0	24
68	Neuroinflammation is highest in areas of disease progression in semantic dementia. <i>Brain</i> , 2021, 144, 1565-1575.	7.6	23
69	β -Amyloid1-40 Increases Expression of β -Amyloid Precursor Protein in Neuronal Hybrid Cells. <i>Journal of Neurochemistry</i> , 2002, 65, 2373-2376.	3.9	18
70	Increased MEPP frequency as an early sign of experimental immune-mediated motoneuron disease. <i>Annals of Neurology</i> , 1990, 28, 329-334.	5.3	17
71	Activated microglia: The silent executioner in neurodegenerative disease?. <i>Current Neurology and Neuroscience Reports</i> , 2001, 1, 303-305.	4.2	17
72	Choice Reaction Time Modifiability in Dementia and depression. <i>International Journal of Neuroscience</i> , 1985, 26, 1-7.	1.6	16

#	ARTICLE	IF	CITATIONS
73	Purification and Characterization of a Central Cholinergic Enhancing Factor from Rat Brain: Its Identity as Phosphoethanolamine. <i>Journal of Neurochemistry</i> , 1989, 53, 448-458.	3.9	14
74	Tregs Attenuate Peripheral Oxidative Stress and Acute Phase Proteins in <scp>ALS</scp>. <i>Annals of Neurology</i> , 2022, 92, 195-200.	5.3	14
75	Extracellular Vesicles Derived From Ex Vivo Expanded Regulatory T Cells Modulate In Vitro and In Vivo Inflammation. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	14
76	Phosphoethanolamine Enhances High-Affinity Choline Uptake and Acetylcholine Synthesis in Dissociated Cell Cultures of the Rat Septal Nucleus. <i>Journal of Neurochemistry</i> , 1992, 59, 236-244.	3.9	11
77	Interaction of myasthenic immunoglobulins and cholinergic agonists on acetylcholine receptors of rat myotubes. <i>Annals of Neurology</i> , 1982, 11, 22-27.	5.3	10
78	Trial of immunosuppression in amyotrophic lateral sclerosis using total lymphoid irradiation. <i>Annals of Neurology</i> , 1994, 36, 253-254.	5.3	10
79	Protective role of heme oxygenaseâ€1 in oxidative stressâ€induced neuronal injury. <i>Journal of Neuroscience Research</i> , 1999, 56, 652-658.	2.9	9
80	Acetylcholine receptor in myasthenia gravis: Increased affinity for ?-bungarotoxin. <i>Annals of Neurology</i> , 1978, 4, 250-252.	5.3	7
81	Multimodal ¹⁸F-AV-1451 and MRI Findings in Nonfluent Variant of Primary Progressive Aphasia: Possible Insights on Nodal Propagation of Tau Protein Across the Syntactic Network. <i>Journal of Nuclear Medicine</i> , 2020, 61, 263-269.	5.0	7
82	Fast Progression in Amyotrophic Lateral Sclerosis Is Associated With Greater TDP-43 Burden in Spinal Cord. <i>Journal of Neuropathology and Experimental Neurology</i> , 2021, 80, 754-763.	1.7	7
83	Stem cells in amyotrophic lateral sclerosis. <i>Neurology</i> , 2016, 87, 348-349.	1.1	6
84	Serum programmed cell death proteins in amyotrophic lateral sclerosis. <i>Brain, Behavior, & Immunity - Health</i> , 2021, 12, 100209.	2.5	6
85	Trophic Effects of Skeletal Muscle Extracts on Spinal Cord Cultures. <i>International Journal of Neuroscience</i> , 1989, 47, 203-208.	1.6	4
86	The Lambert-Eaton Syndrome. <i>Hospital Practice (1995)</i> , 1992, 27, 101-116.	1.0	4
87	The immune system continues to knock at the ALS door. <i>Neuromuscular Disorders</i> , 2016, 26, 335-336.	0.6	3
88	Antibodies from patients with Parkinson's disease react with protein modified by dopamine oxidation. <i>Journal of Neuroscience Research</i> , 1998, 53, 551-558.	2.9	3
89	Calcium binding proteins in selective vulnerability of motor neurons. , 2005, , 65-79.		2
90	AALSS. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2004, 5, 94-98.	1.2	1

#	ARTICLE	IF	CITATIONS
91	The differential in vitro stimulation of 3',5'-cyclic nucleotide phosphodiesterase by calcium binding proteins. IUBMB Life, 1997, 43, 1195-1205.	3.4	0
92	Radicava/Edaravone Findings in Biomarkers From Amyotrophic Lateral Sclerosis (REFINE-ALS): Protocol and Study Design. Neurology: Clinical Practice, 2021, 11, e472-e479.	1.6	0